A practical reference on circular dichroism: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-06-25. Anything still debated is marked as such rather than presented as settled.
Stability depends strongly on physical form. The dry powder is generally regarded as stable for extended periods when held at or below minus twenty degrees Celsius in a sealed, desiccated container. In solution, degradation pathways include deamidation of asparagine and glutamine residues, oxidation of methionine, and aggregation. Reaction rates for these pathways rise with temperature. Repeated freezing and thawing of solutions promotes aggregation, and light exposure can accelerate some oxidative changes. Buffer composition and pH influence which pathway dominates at a given temperature.
Regulatory and quality discussions place the peptide within established guidance for synthetic peptides and biologics. Forced degradation studies, in which samples are exposed to heat, acid, base, peroxide, and light, identify likely degradation products and validate the selectivity of analytical methods. Reference standards allow comparison across laboratories and production batches. Purity specifications reported in the literature usually combine chromatographic purity with mass confirmation. Which impurity thresholds are meaningful for long-term behavior is still debated, and no single universal specification has been adopted across all jurisdictions.
Structure-activity work shows that fatty acid length, linker chemistry and the position of acylation all influence albumin affinity and receptor potency. Plasma protein binding exceeds 99 percent, which restricts distribution and slows renal clearance. Degradation proceeds largely through general proteolysis and fatty acid oxidation rather than cytochrome P450 metabolism, so exposure to common oxidative drug interactions is limited. Whether these clearance routes vary meaningfully between individuals is not fully established.
The molecule is a synthetic 39-amino-acid peptide whose backbone derives from the sequence of human glucose-dependent insulinotropic polypeptide, with several substitutions that raise metabolic stability and shift receptor preference. A C20 fatty diacid is attached through a short linker to a lysine side chain, a modification that increases binding to serum albumin. The reported monoisotopic mass is approximately 4813 Da. Near neutral pH the peptide carries a net negative charge, and the lipid tail makes the molecule markedly more hydrophobic than the unmodified parent sequence.
Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.
| Property | Value | Notes |
|---|---|---|
| Primary purity method | Reversed-phase HPLC | Ultraviolet detection near 214 nm |
| Identity confirmation | Intact mass by LC-MS | Compared with theoretical average mass |
| Sequence verification | Enzymatic peptide mapping | Tandem mass spectrometry of fragments |
| Common degradation route | Deamidation and oxidation | Rate increases with pH and temperature |
| Reference material | Lyophilized peptide standard | Stored desiccated below -20 °C |
An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.
Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
Maurice "Moe" Granat (84) (2007) Gladys Millard (87) (2011) Helen Matheson (95) (2011) Mary Zurawinski (96) (2011) Helen Young (90) (2013) Maureen Pickering (79) (2014) While at Caressant Care, Wettlaufer also injected Michael Priddle (63) and Wayne Hedges (57) "with intent to murder". She confessed to two counts of attempted murder in these cases. She left employment at Caressant Care in 2014, but in part-time work at other facilities and at patients' homes, she injected three more people with insulin:
=== Works cited === Army Techniques Publication 7-100.3: Chinese Tactics (PDF). Washington, D.C.: Headquarters, United States Army. 2021. ISBN 9798457607118. Goldstein, Melvyn C. (1997). The Snow Lion and the Dragon: China, Tibet, and the Dalai Lama. University of California Press. ISBN 978-0-520-21254-1. International Institute for Strategic Studies (12 February 2025). The Military Balance 2025. London: Routledge. doi:10.4324/9781003630760. ISBN 978-1-003-63076-0. Kaufman, Alison A.; Mackenzie, Peter W. (2009). The Culture of the Chinese People's Liberation Army (Report). Marine Corps Intelligence Activity. Archived from the original on 23 June 2024. Retrieved 23 June 2024. Pollpeter, Kevin; Allen, Kenneth W., eds. (14 June 2012). The PLA as Organization v2.0 (Report). China Aerospace Studies Institute. Saunders, Phillip C.; Ding, Arthur S.; Scobell, Andrew; Yang, Andrew N.D.; Joel, Wuthnow, eds. (2019). Chairman Xi Remakes the PLA: Assessing Chinese Military Reforms. Washington, D.C.: National Defense University Press. ISBN 978-1070233420. International Institute for Strategic Studies (2025). The Military Balance 2025. London: Routledge. ISBN 978-1-041-04967-8.
Metallothionein (MT) is a family of cysteine-rich, low molecular weight (MW ranging from 500 to 14000 Da) proteins. They are localized to the membrane of the Golgi apparatus. MTs have the capacity to bind both physiological (such as zinc, copper, selenium) and xenobiotic (such as cadmium, mercury, silver, arsenic, lead) heavy metals through the thiol group of its cysteine residues, which represent nearly 30% of its constituent amino acid residues. MT was discovered in 1957 by Vallee and Margoshe from purification of a cadmium-binding protein from horse (equine) renal cortex. MT plays a role in the protection against metal toxicity and oxidative stress, and is involved in zinc and copper regulation. There are four main isoforms expressed in humans (family 1, see chart below): MT1 (subtypes A, B, E, F, G, H, L, M, X), MT2, MT3, and MT4. In the human body, large quantities are synthesised primarily in the liver and kidneys. Their production is dependent on availability of the dietary minerals such as zinc, copper, and selenium, as well as the amino acids histidine and cysteine. Metallothioneins are rich in thiols, causing them to bind a number of trace metals. Metallothionein is one of the few eukaryotic proteins playing a substantial role in metal detoxification. Zinc and cadmium are tetrahedrally coordinated to cysteine residues, and each metallothionein protein molecule may bind up to 7 atoms of Zn or Cd. The biosynthesis of metallothionein appears to increase several-fold during periods of oxidative stress to shield the cells against cytotoxicity and DNA damage.
In November 1971, Douglas-Home renewed contacts with Salisbury and announced a proposed agreement that would be satisfactory to both sides – it recognised Rhodesia's 1969 constitution as the legal frame of government, while agreeing that gradual legislative representation was an acceptable formula for unhindered advance to majority rule. Nevertheless, the new settlement, if approved, would also implement an immediate improvement in black political status, offer a means to terminate racial discrimination, and provide a solid guarantee against retrogressive constitutional amendments. Implementation of the proposed settlement hinged on popular acceptance, but the Rhodesian government consistently refused to submit it to a universal referendum. A twenty four-member commission headed by an eminent jurist, Lord Pearce, was therefore tasked with ascertaining public opinion on the subject. In 1972, the commission began interviewing interest groups and sampling opinions – although concern was expressed over the widespread apathy encountered. According to the commission, whites were in favour of the settlement, and Rhodesians of Coloured or Asian ancestry generally pleased, while the black response to the settlement's terms was resoundingly negative. As many as thirty black Rhodesian chiefs and politicians voiced their opposition, prompting Britain to withdraw from the proposals on the grounds of the commission's report.
Alkyllithiums and aryllithiums may also react with N,N-disubstituted amides to give aldehydes and ketones, and symmetrical ketones by reacting with carbon monoxide. They thermally decompose to eliminate a β-hydrogen, producing alkenes and lithium hydride: another route is the reaction of ethers with alkyl- and aryllithiums that act as strong bases. In non-polar solvents, aryllithiums react as the carbanions they effectively are, turning carbon dioxide to aromatic carboxylic acids (ArCO2H) and aryl ketones to tertiary carbinols (Ar'2C(Ar)OH). Finally, they may be used to synthesise other organometallic compounds through metal-halogen exchange.
Sources: en.wikipedia.org
=== Cold mixed absinthe === Many modern absinthes are produced using a cold-mix process. This inexpensive method of production does not involve distillation, and is regarded as inferior for the same reasons that give cause for cheaply compounded gin to be legally differentiated from distilled gin. The cold mixing process involves the simple blending of flavouring essences and artificial colouring in commercial alcohol, in similar fashion to most flavoured vodkas and inexpensive liqueurs and cordials. Some modern cold-mixed absinthes have been bottled at strengths approaching 90% ABV. Others are presented simply as a bottle of plain alcohol with a small amount of powdered herbs suspended within it. The lack of a formal legal definition in most countries to regulate the production and quality of absinthe has enabled cheaply made products to be falsely presented as traditional in production and composition. In Switzerland, the only country with a formal legal definition of absinthe, any absinthe product not obtained by maceration and distillation or coloured artificially cannot be sold as absinthe.
Raw brown mushrooms are 92% water, 4% carbohydrates, 2% protein and less than 1% fat (table). In a reference amount of 100 grams (3.5 oz), raw brown mushrooms provide 22 calories, and are a rich source (20% or more of the Daily Value, DV) of B vitamins, such as riboflavin, niacin and pantothenic acid, selenium (47% DV) and copper (56% DV) (table). They are a moderate source of phosphorus, zinc and potassium (10–15% DV). They have minimal or no vitamin C or sodium content.
=== Type II === A civilization capable of harnessing the energy radiated by its own large star – for example, by successfully completing a Dyson sphere or Matrioshka brain – with an energy consumption of ≈4×1033 erg/s. Lemarchand defined such civilizations as being able to harness and channel the entire radiation output of their star. The energy consumption would then be comparable to the luminosity of the Sun, ≈4×1033 erg/s" (≈4×1026 watts).
== Taxonomy == FishBase recognizes four species in the genus. In addition to these, evidence suggests that a fifth species, A. arapaima, should be recognized (this being the widespread, well-known species, otherwise included in A. gigas).
== Manufacturing == Although pseudoephedrine occurs naturally as an alkaloid in certain plant species (for example, as a constituent of extracts from the Ephedra species, also known as ma huang, in which it occurs together with other isomers of ephedrine), the majority of pseudoephedrine produced for commercial use is derived from yeast fermentation of dextrose in the presence of benzaldehyde. In this process, specialized strains of yeast (typically a variety of Candida utilis or Saccharomyces cerevisiae) are added to large vats containing water, dextrose and the enzyme pyruvate decarboxylase (such as found in beets and other plants). After the yeast has begun fermenting the dextrose, the benzaldehyde is added to the vats, and in this environment, the yeast converts the ingredients to the precursor l-phenylacetylcarbinol (L-PAC). L-PAC is then chemically converted to pseudoephedrine via reductive amination. The bulk of pseudoephedrine is produced by commercial pharmaceutical manufacturers in India and China, where economic and industrial conditions favor its mass production for export.
Sources: en.wikipedia.org
Peptide mapping with tandem mass spectrometry is the standard approach. The peptide is digested with an enzyme such as trypsin, and the resulting fragments are matched against the expected sequence.
Higher pH and elevated temperature both increase deamidation rates. Holding solutions at low temperature and near-neutral to slightly acidic pH reduces the extent of the reaction.
Removing water slows hydrolysis and aggregation. The dry powder tolerates longer storage intervals than a solution kept at the same temperature.
It is a synthetic peptide of 39 amino acids bearing a lipid side chain. Its size and architecture place it outside the small-molecule class, and laboratories generally handle it with the precautions used for biologic-like molecules.